Biotech Values

[DewDiligence]

What you posit is a supply-constrained market where the supply constraint is the budget rather than the system throughput (as in my ENTA valuation model). I would classify your scenario under premise b in #msg-99174021 insofar as it’s fundamentally distinct from any model in which HCV sales are constrained by demand.